Core Viewpoint - The company announced plans to present multiple obesity drug candidates, including ASC30 and the ASC31 and ASC47 combination therapy, at the 2025 ObesityWeek® in Atlanta, Georgia [1] Group 1 - The presentation will be in the form of a poster at the ObesityWeek® event [1] - The founder and CEO, Dr. Wu Jinzi, expressed excitement about the ongoing progress of their small molecule and peptide obesity pipeline [1] - The advancements reflect the company's commitment to developing highly differentiated obesity treatment solutions [1]

Core Insights - The company announced that it will present multiple obesity drug candidates, including ASC30 and the combination therapy of ASC31 and ASC47, at the 2025 ObesityWeek in Atlanta, Georgia [1] - The CEO expressed excitement about the progress of their small molecule and peptide obesity pipeline, highlighting the company's commitment to developing differentiated obesity treatment options [1] Company Developments - The company is actively advancing its obesity treatment pipeline, showcasing its candidates at a significant industry event [1] - The announcement reflects the company's strategic focus on addressing obesity through innovative therapies [1]

Core Viewpoint - The company, Gilead Sciences-B (01672.HK), announced its participation in the 2025 Obesity Week in Atlanta, Georgia, where it will present multiple obesity treatment candidates, including ASC30, ASC31, and ASC47 combination therapy [1] Group 1: Presentation Details - The company will report on the oral GLP-1 receptor biased small molecule agonist ASC30 in a 28-day multiple ascending dose study [1] - An Ib phase study on ASC30, a monthly subcutaneous injection small molecule GLP-1 receptor agonist in obese subjects, will also be presented [1] - The combination of GLP-1 receptor/GLP receptor agonist peptides ASC31 and ASC47 showed a relative weight loss improvement of 119.6% compared to tirzepatide in diet-induced obese mice [1] Group 2: Company Statements - The founder, chairman, and CEO of the company expressed excitement about the ongoing progress of their small molecule and peptide obesity pipeline, highlighting a strong commitment to developing differentiated obesity treatment solutions [1]